SAN DIEGO, April 25 /PRNewswire-FirstCall/ -- Protein Polymer
Technologies, Inc. (OTC Bulletin Board: PPTI), announced today that James B.
McCarthy, M.B.A., J.D. has been elected to its Board of Directors.  Having
recently selected a new CEO, PPTI is expanding the Board of Directors.
    "James McCarthy brings over 30 years of global experience in the
healthcare, medical device, and biotech manufacturing fields to our company,"
said William N. Plamondon, PPTI's newly appointed CEO.  "His expertise in
planning and analysis will prove to be a great asset to our Board."
    McCarthy is Chairman and Chief Executive Officer of Gemini Consulting
Group, Inc., Oak Brook, IL, a company specializing in the development of
hospitals and specialty medical facilities in both the U.S. and overseas.
He has also held senior management positions for a Chicago-based health care
consulting company, a medical device manufacturing company, and the Medical
Products Division of 3M Company.  McCarthy has a BA from the University of
Notre Dame, a J.D. from Loyola University School of Law, and an MBA from the
Keller Graduate School of Management.  He sits on several boards including
Wintrust Financial Corporation, Lake Forest, IL, and Sirigen, Inc., Santa
Barbara, CA.  "I am delighted to be joining the Board of Protein Polymer
Technologies," said McCarthy.  "I look forward to working with the Board and
Management on the expansion and ongoing development of the company's exciting
technologies and products."

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes.  From its
inception in 1988, PPTI has been a pioneer in protein design and synthesis,
creating an extensive portfolio of proprietary biomaterials for use in the
development of bioactive devices.  These genetically engineered biomaterials
are high molecular weight proteins, processed into products with physical and
biological characteristics tailored to specific clinical performance
requirements.  Targeted products include urethral bulking agents for the
treatment of stress urinary incontinence, dermal augmentation products for
cosmetic and reconstructive surgery, surgical adhesives and sealants,
scaffolds for wound healing and tissue engineering, and depots for local drug
delivery.  To date, PPTI has been issued twenty-six U.S. Patents on its core
technology with corresponding issued and pending patents in key international
markets.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include raising adequate capital to continue operations, scientific
and clinical product development uncertainties, competitive products and
approaches, continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale-up.  The reader is
encouraged to refer to the Company's 2004 Annual Report on Form 10-KSB, and
other recent filings with the Securities and Exchange Commission, copies of

which are available from the Company, to further ascertain the risks
associated with the above statements.

Link to this page: